ClearPoint Neuro (NASDAQ:CLPT) Releases Earnings Results, Misses Expectations By $0.05 EPS

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05), Zacks reports. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The firm had revenue of $7.77 million during the quarter, compared to analysts' expectations of $8.23 million. ClearPoint Neuro updated its FY 2025 guidance to EPS.

ClearPoint Neuro Trading Up 2.3 %

Shares of ClearPoint Neuro stock traded up $0.32 during trading on Friday, hitting $14.52. The stock had a trading volume of 346,046 shares, compared to its average volume of 230,075. The firm has a market cap of $401.22 million, a price-to-earnings ratio of -21.04 and a beta of 1.03. ClearPoint Neuro has a 12 month low of $5.11 and a 12 month high of $19.22. The business's 50-day moving average is $16.64 and its 200 day moving average is $13.90.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CLPT shares. B. Riley boosted their target price on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Lake Street Capital boosted their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a "buy" rating in a report on Tuesday, January 21st.

Remove Ads

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.